Date published: 2026-7-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

NCKX5 CRISPR/Cas9 KO Plasmid (h): sc-405875

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • NCKX5 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the NCKX5 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NCKX5 Antibody (A-6): sc-515715
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    NCKX5 CRISPR/Cas9 KO Plasmid (h)

    sc-405875
    20 µg
    $397.00

    Overview

    SLC24A5 encodes NCKX5, a potassium-dependent sodium/calcium exchanger that regulates melanosomal ion homeostasis and supports proper melanogenesis in pigment-producing cells. By tuning Ca²⁺ flux and ionic balance within the endomembrane system, NCKX5 influences melanin synthesis, melanosome maturation, and pigment deposition pathways. Genetic variation in SLC24A5 is strongly associated with normal-range differences in human pigmentation, and altered activity is commonly examined in the context of melanocyte biology. As a membrane transporter with roles in intracellular trafficking and organelle function, NCKX5 provides a mechanistic entry point to study ion transport control of pigmentation programs.

    NCKX5 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SLC24A5 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SLC24A5 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SLC24A5 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NCKX5 protein expression.

    This CRISPR knockout system enables efficient generation of SLC24A5-deficient cell models for investigation of NCKX5 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting SLC24A5 exon(s) critical for NCKX5 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple SLC24A5 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by NCKX5 CRISPR/Cas9 KO Plasmid (h) and NCKX5 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SLC24A5 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by NCKX5 HDR Plasmid (h) and NCKX5 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SLC24A5 homology arms to support homology-directed repair at defined SLC24A5 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.